Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

15 / 39

Crizotinib beyond PD and local treatment
PROFILE 1014
Median OS after BM development
49.5 mo.
Salomon – JCO 2018 * Johung - JCO 2016
RETROSPECTIVE
Median TBP
was 20.4 weeks